Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 563-576

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Agomelatine; Antidepressant; Major depression; Melatonin; Serotonin

Indexed keywords

EID: 70449730247     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/ndt.s5453     Document Type: Note

References (84)

1. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP task force on response and remission in major depression. Neuropsychopharmacol. 2006;31:1841-1853. (Pubitemid 44246330)
2. Howland RH. Chronic depression. Hosp Community Psychiatry. 1993;44:633-639.
3. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63:963-971. (Pubitemid 35388053)
4. Dunner DL, Rush AJ, Russell JM, et al. Prospective long-term multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688-695.
5. Howland RH. Health status, health care utilization, and medical comorbidity in dysthymia. Int J Psychiatry Med. 1993;23:211-238.
6. Howland RH, Schettler PJ, Rapaport MH, et al. Clinical features and functioning of patients with minor depression. Psychother Psychosom. 2008;77:384-389.
7. Koplan C, Charuvastra A, Compton MT, et al. Prevention psychiatry. Psychiatr Ann. 2007;37:319-328.
8. Baune BT, Adrian I, Jacobi F. Medical disorders affect health outcome and general functioning depending on comorbid major depression in the general population. J Psychosomatic Res. 2007;62:109-118. (Pubitemid 46161593)
9. Carney RM, Freedland KE. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry. 2009;166:410-417.
10. Rivelli S, Jiang W. Depression and ischemic heart disease: What have we learned from clinical trials? Curr Opin Cardiol. 2007;22:286-291. (Pubitemid 46900753)
11. Carnethon MR, Biggs ML, Barzilay JI, et al. Longitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adults. Arch Intern Med. 2007;167:802-807.
12. Diem SJ, Blackwell TL, Stone KL, et al. Depressive symptoms and rates of bone loss at the hip in older women. J Am Geriactr Soc. 2007;55:824-831.
13. Spernak SM, Moore PJ, Hamm LF. Depression, constructive thinking, and patient satisfaction in cardiac treatment adherence. Psychol Health Med. 2007;12:172-189. (Pubitemid 46255599)
14. Kilbourne AM, Reynolds CF, Good CB, Sereika SM, Justice AC, Fine MJ. How does depression influence diabetes medication adherence in older patients? Am J Geriat Psychiatry. 2005;13:202-210.
15. Mohr DC, Goodkin DE, Likosky W, Gatto N. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurology. 1997;54:531-533. (Pubitemid 27204238)
16. Safren SA, Hendricksen ES, Mayer KH, Mimiaga MJ, Pickard R, Otto MW. Cognitive-behavioral therapy for HIV medication adherence and depression. Cogn Behav Pract. 2004;11:415-424. (Pubitemid 43225380)
17. Knol MJ, Twisk JW, Beekman AT, Heine RJ, Snoek FJ, Pouwer F. Depression as a risk factor for the onset of type 2 diabetes mellitus: A meta-analysis. Diabetologia. 2006;49:837-845.
18. Gold DT, Solimeo S. Osteoporosis and depression: A historical perspective. Curr Osteoporos Rep. 2006;4:134-139.
19. Ilias I, Alesci S, Gold PW, Chrousos GP. Depression and osteoporosis in men: Association or casual link? Hormones. 2006;5:9-16.
20. O'Keane V, Marsh MS. Depression during pregnancy. BMJ. 2007;334:1003-1005.
21. Wisner KL, Zarin DA, Holmboe ES, et al. Risk-benefit decision making for treatment of depression during pregnancy. JAMA. 2000;157:1933-1940.
22. Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68(Suppl 10):8-10.
23. Hamon M, Bourgoin S. Pharmacological profile of antidepressants: A likely basis for their efficacy and side effects? Eur Neuropsychopharmacol. 2006;16:S625-S632. (Pubitemid 44550176)
24. Dubocovich ML. Drug evaluation: Agomelatine targets a range of major depressive disorder symptoms. Curr Opin Investig Drugs. 2006;7:670-680.
25. European Medicines Agency. CMHP Assessment Report For Valdoxan. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/valdoxan/H-915-en6.pdf. Accessed November 20, 2008.
26. European Medicines Agency. Committee For Medicinal Products For Human Use Summary of Positive Opinion for Valdoxan. URL: http://www.emea.europa.eu/pdfs/ human/opinion/Valdoxan-57541108en.pdf. Accessed November 20, 2008.
27. European Medicines Agency. Valdoxan Product Information. Summary of Product Characteristics. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ valdoxan/H-915-PI-en.pdf.
28. US National Institutes of Health. URL: http://www.clinicaltrials.gov.
29. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm Chem Life Sci. 2005;338:229-247. (Pubitemid 40957262)
30. Wirz-Justice A. Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol. 2006;21(Suppl 1):S11-S15. (Pubitemid 43740327)
31. Wehr TA. Photoperiodism in humans and other primates: Evidence and implications. J Biol Rhythms. 2001;16:348-364.
32. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B, Hardeland R. Melatonin: Nature's most versatile biological signal? FEBS J. 2006;273:2813-2838. (Pubitemid 43910039)
33. Pandi-Perumal SR, Srinivasan V, Spence DW, Cardinali DP. Role of the melatonin system in the control of sleep: Therapeutic implications. CNS Drugs. 2007;21:995-1018. (Pubitemid 350136783)
34. Rajaratnam SMW, Cohen DA, Rogers NL. Melatonin and melatonin analogues. Sleep Med Clin. 2009;4:179-193.
35. Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: Mutual improvement of sleep, cognition, and mood? Eur J Neurosci. 2009;29:1795-1809.
36. Millan MJ, Gobert A, Lejeune F, et al. The novel melatonin agonist agomelatine is an antagonist at 5-hydoxytryptamine-2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther. 2003;306:954-964. (Pubitemid 37025301)
37. Egerton A, Ahmad R, Hirani E, Grasby PM. Modulation of striatal dopamine release by 5-HT2A and 5-HT2C receptor antagonists: [11C]raclopride PET studies in the rat. Psychopharmacology. 2008;200:487-496.
38. Shelton RC, Papakostas GI. Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder. Acta Psychiatr Scand. 2008;117:253-259. (Pubitemid 351350599)
39. Quera-Salva MA, Vanier B, Laredo J, et al. Major depressive disorder, sleep EEG and agomelatine: An open-label study. Int J Neuropsychopharmacol. 2007;10:691-696. (Pubitemid 47517524)
40. Kupfer DJ. Depression and associated sleep disturbances: Patient benef its with agomelatine. Eur Neuropsychopharmacol. 2006;16(Suppl 5):S639-S643.
41. Leproult R, Van Onderbergen A, L'Hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body termperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol. 2005;63:298-304. (Pubitemid 41233447)
42. Descamps A, Rousset C, Millan M, Spedding M, Delagrange P, Cespuglio R. Influence of the novel antidepressant and melatonin agonist/serotonin2C receptor antagonist, agomelatine, on the rat sleep-wake cycle architecture. Psychopharmaology. 2009;2005:93-106.
43. Racagni G, Riva MA, Popoli M. The interaction between the internal clock and antidepressant efficacy. Int Clin Psychopharmacol. 2007;22(Suppl 2):S9-S14. (Pubitemid 47530848)
44. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
45. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925-935.
46. Wenk GL, Parsons CG, Danysz W. Potential role of N-methyl-Daspartate receptors as executors of neurodegeneration resulting from diverse insults: Focus on memantine. Behav Pharmacol. 2006;17:411-424. (Pubitemid 44325803)
47. Heine VM, Maslam S, Zareno J, Joels M, Lucassen PJ. Suppressed proliferation and apoptotic changes in the rat dentate gyrus after acute and chronic stress are reversible. Eur J Neuroscience. 2004;19:131-144. (Pubitemid 38122079)
48. Einat H, Manji HK. Cellular plasticity cascades: Genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry. 2006;59:1160-1171. (Pubitemid 43949143)
49. Banasr M, Soumier A, Hery M, Mocaer E, Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry. 2007;59:1087-1096. (Pubitemid 43849657)
50. Gressens P, Schwendimann L, Husson I, et al. Agomelatine, a melatonin receptor agonist with 5-HT2C receptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur J Pharmacol. 2008;588:58-63.
51. Barbiero VS, Zappettini S, Mocaer E, et al. The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus. Eur Neuropyschopharmacol. 2007;17(Suppl 4):S365.
52. Calabrese F, Pescara F, Racagni G, Mocaer E, Molteni R, Riva MA. Modulation of Arc and BDNF following acute and chronic administration of agomelatine in rats. Eur Neuropyschopharmacol. 2007;17(Suppl 4):S333-S334.
53. Soumier A, Banasr M, Lortet S, et al. Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology. DOI: 10.1038/npp.2009.72.
54. Conboy L, Tanrikut C, Zoladz PR, et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol. 2009;12:329-341.
55. Paizanis E, Lelievre V, Saurini F, et al. Effects of agomelatine and fluoxetine on hippocampal cell survival, glucocorticoid receptors, and BDNF expression in a model of depression. Eur Neuropyschopharmacol. 2008;18(Suppl 4):S316.
56. Zupancic M, Guilleminault C. Agomelatine: A preliminary review of a new antidepressant. CNS Drugs. 2006;20:981-992. (Pubitemid 44912707)
57. Dolder CR, Nelson M, Snider M. Agomelatine treatment of major depressive disorder. Ann Pharmacother. 2008;42:1822-1831.
58. Loo H, Hale A, D'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychopharmacol. 2002;17:239-247.
59. Kennedy SH, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol. 2006;16(2):93-100. (Pubitemid 43145814)
60. Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10:661-673.
61. Goodwin GM, Emsley R, Rembry S, Rouillon F; for the Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized double-blind placebo-controlled trial. J Clin Psychiatry. In Press.
62. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol. 2008;28:329-333.
63. Montejo AL, Prieto N, Terleira A, et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week placebo-controlled study using the PRSEXDQ-SALSEX scale. J Psychopharmacol OnlineFirst. DOI:10.1177/0269881108096507 November 21, 2008.
64. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: Randomized double-blind comparison with venlafaxine. J Clin Psychiatry. 2007;68:1723-1732. (Pubitemid 350247502)
65. Wulff K, Bayle F, Hajak G, et al. Exploratory study of actigraphic and psychometric measures in depressed patients treated with agomelatine or sertraline (abstract). Eur Neuropsychopharmacol. 2007;17(Suppl 4):S326.
66. Kasper S, Laigle L, Bayle F. Superior antidepressant efficacy of agomelatine versus sertraline: A randomised double-blind study (abstract). Eur Neuropsychopharmacol. 2008;18(Suppl 4):S336-S337.
67. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19(5):271-280. (Pubitemid 39141943)
68. Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized anxiety disorder: A randomized double-blind placebo-controlled study. J Clin Psychopharmacol. 2008;28:561-566.
69. Fabiano A, de Leersnyder H. Agomelatine efficacy on major sleep disturbances in Smith-Magenis syndrome: An exploratory open study in children (abstract). Eur Neuropsychopharmacol. 2007;17(Suppl 4):S567.
70. Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. Am J Psychiatry. 2009;166:599-607.
71. Howland RH, Thase ME. Mood disorders: Therapeutic armamentarium. In: D'haenen H, den Boer JA, Willner P, Eds. Biological Psychiatry. London, England: John Wiley & Sons, Ltd; 2002:861-875.
72. Howland RH. Medication adherence. Psychiatr Ann. 2008;38:323-326.
73. Howland RH. Limitations of evidence in the practice of evidence-based medicine. Psychiatr Ann. 2008;38:334-336.
74. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: A STAR*D report. Am J Psychiatry. 2007;164:753-760. (Pubitemid 46808530)
75. Loo H, Dalery J, Macher JP. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders [article in French]. Encephale. 2002;28:356-362.
76. Howland RH. Evaluating the safety of medications during pregnancy and lactation. J Psychosoc Nurs Ment Health Serv. 2009;47:19-22.
77. Howland RH. Prescribing psychotropic medications during pregnancy and lactation: Principles and guidelines. J Psychosoc Nurs Ment Health Serv. 2009;47:19-23.
78. Trivedi MH, Rush AJ, Gaynes BN, et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology. 2007;32:2479-2489.
79. Howland RH. An overview of seasonal affective disorder and its treatment. The Physician and Sportsmedicine. In press.
80. Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM. Bidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatine. Prog Neurobiol. 2009;88:264-271.
81. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord. 2007;9:628-635. (Pubitemid 47365631)
82. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology. 2007;190:575-579. (Pubitemid 46204474)
83. Howland RH. Current research in treatment-resistant depression: When to augment and when to switch. MedscapeCME Psychiatry and Mental Health. Published Online July 23, 2009, URL: http://cme.medscape. com/viewarticle/705917.
84. Howland RH. Understanding the clinical profile of a drug on the basis of its pharmacology: Mirtazapine as an example. J Psychosoc Nurs Ment Health Serv. 2008;46:19-23.